Overview

Enclomiphene citrate is a selective estrogen receptor modulator (SERM) that represents the more active trans-isomer of clomiphene citrate. Unlike traditional testosterone replacement therapy, enclomiphene works by blocking estrogen receptors in the hypothalamus and pituitary gland, leading to increased production of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This stimulates the testes to produce testosterone naturally while maintaining fertility.

Research indicates that enclomiphene can effectively raise testosterone levels in men with secondary hypogonadism while preserving sperm production, making it an attractive alternative to exogenous testosterone therapy for men who wish to maintain fertility.

Mechanism of Action

Enclomiphene functions as a competitive antagonist at estrogen receptors in the hypothalamic-pituitary axis. Under normal conditions, testosterone is converted to estradiol via aromatase, and this estradiol provides negative feedback to the hypothalamus and pituitary, suppressing gonadotropin-releasing hormone (GnRH), LH, and FSH production.

By blocking estrogen receptors, enclomiphene prevents this negative feedback loop, leading to:

1. Increased GnRH release from the hypothalamus
2. Elevated LH and FSH secretion from the pituitary
3. Enhanced testicular stimulation resulting in increased testosterone and sperm production
4. Preservation of the hypothalamic-pituitary-testicular axis unlike exogenous testosterone

This mechanism allows for testosterone restoration while maintaining natural hormonal feedback systems and fertility.

Research Summary

Clinical evidence for enclomiphene is based on multiple randomized controlled trials and systematic reviews. Studies consistently demonstrate efficacy in raising testosterone levels while preserving fertility parameters.

Key Studies

Oral enclomiphene citrate stimulates testosterone production (2013): A phase II study comparing enclomiphene to testosterone gel found that 25mg daily enclomiphene increased total testosterone from 248 ng/dL to 540 ng/dL over 3 months while maintaining sperm concentrations, unlike testosterone gel which suppressed sperm production.

Randomized phase II clinical trial (2014): This study in 124 hypogonadal men showed enclomiphene 12.5mg and 25mg daily both significantly increased testosterone levels (to 441 and 510 ng/dL respectively) compared to placebo, with concurrent increases in LH and FSH levels.

Systematic review and meta-analysis (2025): Recent comprehensive analysis of randomized controlled trials confirmed enclomiphene's efficacy in treating male hypogonadism while preserving fertility, with effect sizes comparable to testosterone replacement but superior fertility outcomes.

Obese hypogonadal men study (2016): In overweight men with secondary hypogonadism, enclomiphene 25mg daily raised testosterone levels significantly while preserving sperm counts, demonstrating efficacy even in challenging populations.

Studies consistently report good tolerability with minimal side effects, primarily limited to occasional visual disturbances and mood changes typical of SERMs.

Dosage Guidelines

Dosing protocols are based on FDA-approved guidelines and clinical trial data for secondary male hypogonadism.

Typical Protocol:

• Start with 12.5mg daily for 2-4 weeks
• Increase to 25mg daily if insufficient response
• Monitor testosterone levels at 4-6 weeks
• Continue for 3-6 months before reassessment
• Take with food to improve absorption

Safety Profile

Enclomiphene demonstrates a favorable safety profile in clinical trials, with most adverse events being mild to moderate in severity.

Common Side Effects (>5%):

• Headache
• Nausea
• Diarrhea
• Flushing
• Mood changes

Less Common (<5%):

• Visual disturbances
• Gynecomastia (paradoxical)
• Elevated liver enzymes
• Testicular pain

Monitoring Recommendations:

• Baseline: Total testosterone, LH, FSH, PSA, liver function
• 4-6 weeks: Testosterone levels
• 3 months: Complete hormone panel, PSA, liver function
• Ongoing: Every 6 months during treatment

Important Considerations:

• Not approved for human use in research contexts
• Prescription medication requiring medical supervision
• May cause birth defects if used by pregnant women
• Regular monitoring essential for safety

Stacking

Enclomiphene is typically used as monotherapy but may be combined with certain compounds under medical supervision.

Compatible Approaches:

• With HCG: Sequential use (not concurrent) for enhanced testicular stimulation
• With aromatase inhibitors: May enhance testosterone response but requires careful monitoring
• Post-cycle therapy: Often used after anabolic steroid cycles to restore natural production

Not Recommended:

• Concurrent testosterone replacement (counterproductive)
• Other SERMs (redundant mechanisms)
• Without medical supervision (prescription required)

Enclomiphene represents a significant advancement in treating male hypogonadism while preserving fertility, offering an evidence-based alternative to traditional testosterone replacement therapy.

References

1. Enclomiphene citrate for the treatment of secondary male hypogonadism. (2016). Expert opinion on pharmacotherapy. DOI PubMed
2. Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials. (2025). Archives of endocrinology and metabolism. DOI PubMed
3. Enclomiphene citrate: A treatment that maintains fertility in men with secondary hypogonadism. (2019). Expert review of endocrinology & metabolism. DOI PubMed
4. Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement. (2016). BJU international. DOI PubMed
5. Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone. (2014). Fertility and sterility. DOI PubMed
6. Oral enclomiphene citrate stimulates the endogenous production of testosterone and sperm counts in men with low testosterone: comparison with testosterone gel. (2013). The journal of sexual medicine. DOI PubMed
7. Enclomiphene does not alter the postpartum interval of suckled beef cows. (1991). Journal of animal science. DOI PubMed
8. Effects of enclomiphene and zuclomiphene on basal and gonadotrophin-stimulated progesterone secretion by isolated subpopulations of small and large ovine luteal cells. (1996). Human reproduction (Oxford, England). DOI PubMed
9. Estrogenic and antiestrogenic effects of enclomiphene and zuclomiphene on gonadotropin secretion by ovine pituitary cells in culture. (1983). Endocrinology. DOI PubMed
10. Postpartum interval in beef cows shortened by enclomiphene. (1987). Journal of animal science. DOI PubMed